Inhalable CoQ10 Liposomal Dispersion for Deep Lung Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for delivering therapeutic agents to the lung are often ineffective, inefficient, and cause significant side effects, and struggle to reliably deliver hydrophobic bioactive agents like CoQ10 to the deep lung due to issues with particle size and stability.
Innovation Solution
Development of inhalable pharmaceutical compositions comprising an aqueous dispersion of liposomal particles with CoQ10, where the particles have an average diameter between 30 and 500 nm, and a phospholipid such as DPPC, DSPC, or DMPC, allowing for continuous aerosolization and stable delivery to the deep lung.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Volume of moving object
If mechanical micronization methods such as milling are used to reduce particle size, then particle size is reduced, but thermal and mechanical degradation of the pharmaceutical occurs
Solution Approach 1:
The patent employs spray drying, a phase transition process where an aerosolized solution or suspension undergoes rapid evaporation of the liquid phase to form dry particles. This avoids mechanical stress and thermal degradation associated with milling by using a gentle phase change from liquid to solid state, producing particles in the respirable size range without degrading the pharmaceutical agent.
2Volume of moving object
If spray drying is used to micronize drug substances, then particle size is reduced, but difficulty in collecting small particles occurs
Solution Approach 1:
The patent uses a carrier substance as an intermediary that associates with the drug substance during aerosolization. This carrier-substrate complex allows small drug particles to be effectively generated and delivered, with the carrier providing a matrix that facilitates particle collection and delivery to the lung, overcoming the difficulty of collecting ultrafine drug particles alone.
3Productivity
If conventional aerosol delivery methods are used, then drug delivery to the lung is attempted, but droplets are too large or too inconsistent to reliably deliver a specific dose
Solution Approach 1:
The patent replaces conventional mechanical aerosol generation methods with a vibrating mesh nebulizer that uses ultrasonic vibration to generate aerosol particles. This substitution of the aerosolization mechanism produces highly monodisperse particles with consistent size distribution, enabling reliable dose delivery while maintaining high aerosol output, overcoming the limitations of traditional compressors or jet-based systems.
4Productivity
If particles are delivered to the upper respiratory tract, then initial deposition occurs, but particles are rapidly removed by the mucociliary escalator and swallowed or coughed
Solution Approach 1:
The patent optimizes particle size parameters to fall within the respirable range (1-5 μm aerodynamic diameter), which allows particles to bypass upper respiratory deposition and reach the deep lung and alveoli. This parameter optimization ensures particles are small enough to avoid mucociliary clearance in the upper airways while large enough to be effectively delivered, thereby extending retention time and therapeutic action in the target tissue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions achieve high aerosol output, transmission, and dose delivery, ensuring consistent and therapeutic levels of CoQ10 reach the lung, reducing systemic side effects and improving treatment efficacy for conditions like lung cancer.
Implementation Method 1
liposomal particles comprising a hydrophobic bioactive agent, a phospholipid, and an aqueous dispersion vehicle
Implementation Method 2
each liposomal particle comprising a hydrophobic bioactive agent, a phospholipid, and an aqueous dispersion vehicle
Implementation Method 3
suitable for continuous aerosolization
Implementation Method 4
continuous nebulization of nanodispersions of this hydrophobic drug
Data Source
Figure 1A
Figure 1B
Figure 2~3
AI summary
Inhalable pharmaceutical compositions can include an aqueous dispersion of particles including a hydrophobic bioactive agent (e.g., CoQIO) suitable for continuous aerosolization. Due to their chemical composition and methods of manufacture, the pharmaceutical compositions exhibit distinctive physicochemical properties that provide advantageous aerosol transmission and output.